Citation: Berry-Kravis E, et al. Outcomes in participants with infantile-onset Niemann-Pick disease type C receiving prompt and sustained treatment with adrabetadex. Poster presented at: Child Neurology Society Annual Meeting; October 2026.
The information provided on this website is provided by the Beren Therapeutics P.B.C. (“Beren”) Medical Affairs team for healthcare professionals in the US. It is designed to provide self-service access to medical information and medical affairs content about Beren products, pipeline, and therapeutic areas of interest including clinical data, research developments, congress materials, and publications. Certain materials such as posters and presentations presented in this website are a result of Beren-sponsored research and are not intended to be a comprehensive overview of all information and materials presented at a particular congress. The website is intended to provide scientifically balanced information and educational resources and may include information related to products or indications that have not been approved by the US Food and Drug Administration. The information provided is not intended as medical advice and does not replace independent medical judgement. By searching this website, you confirm the unsolicited nature of your inquiry. Please confirm that you agree and that you are a registered healthcare professional registered to practice in the US.
